

**Issue date**  
**24 October 2023**

**Distributed to:**

Chief Executives  
Directors of Clinical Governance  
Director, Regulation and Compliance Unit

**Action required by:**

Chief Executives  
Directors of Clinical Governance  
Maternal Transfer Redesign and Obstetric Leads

**We recommend you also inform:**

Directors, Managers and Staff of:  
• Maternity Services

**Expert Reference Group**

**Content reviewed by:**

Health and Social Policy Branch, MoH  
Clinical Excellence Commission  
NSW Health Pathology HealthShare  
State Preparedness and Response Unit

**Ministry of Health – Health and Social Policy Branch**

Email: [MOH-HSPB@health.nsw.gov.au](mailto:MOH-HSPB@health.nsw.gov.au)  
[Internet Website](#)  
[Intranet Website](#)

**Review date**  
**March 2024**

**Updated: Supply disruption: Rapid Fetal Fibronectin (fFN) 10Q cassettes**

**What is updated in the Safety Notice from SN:003/23?**

This notice has been updated to advise of ongoing supply disruption.

**Situation**

There continues to be supply disruption of Rapid Fetal Fibronectin 10Q cassettes due to manufacturing issues is ongoing with limited supply expected until February 2024. Stock for regional and remote facilities will continue to be prioritised. An alternative product, Actim Partus, remains available for ordering.

**Background**

Fetal Fibronectin is a biomarker test used to help diagnose the risk of premature labour and birth. This assists in clinical decision making to determine if a pregnant woman requires transfer for higher-level care. Rapid Fetal Fibronectin tests are a quantitative test providing a numerical result that can improve the assessment of risk for preterm birth.

The test is used as part of the decision-making tool (Appendix 2 – page 14) in the NSW Health Policy Directive *Tiered Networking Arrangements for Perinatal Care in NSW* ([PD2023\\_035](#)) and NSW Health Guideline *Management of Threatened Preterm Labour* ([GL2022\\_006](#)).

**Assessment**

There is a small amount of stock available within NSW Health maternity facilities. This stock may not be sufficient for demand levels.

**Clinical Recommendations**

**Conservation Measures:**

Maternal Transfer Redesign and Obstetric Leads are to:

- Communicate within their Tiered Perinatal Network (TPN) to ensure that available stock is appropriately allocated – considering service capability levels and regional and rural locations.
- Ensure stock levels are communicated between TPNs as required.

Rapid Fetal Fibronectin 10Q cassettes should not be used in asymptomatic women.

**Utilisation of Actim Partus tests:**

Assessment and management of women who present with signs and symptoms of threatened preterm labour should continue as per NSW Health Guideline *Management of Threatened Preterm Labour* ([GL2022\\_006](#)).

As Actim Partus tests provide a qualitative result only care must be taken when utilising the *Maternal Transfers Decision Making Tool* (Appendix 2 - [PD2023\\_035](#)). Consultation with the Tiered Perinatal Network should occur to assist with care planning and decision making regarding the need for transfer.

**Required actions for the Local Health Districts/Networks**

1. Distribute this Safety Notice to all relevant clinicians, clinical departments where pregnant women at risk of premature birth receive care.
2. Include this Safety Notice in relevant handovers and safety huddles.

**Report any associated incidents into [ims+](#)**